Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 0.4% – Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares were down 0.4% during mid-day trading on Tuesday . The company traded as low as $28.85 and last traded at $30.40. Approximately 844,399 shares were traded during trading, an increase of 23% from the average daily volume of 685,221 shares. The stock had previously closed at $30.51.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TNXP. Noble Financial restated an “outperform” rating and issued a $70.00 price objective on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th. StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating on the stock.

Tonix Pharmaceuticals Stock Performance

The company’s fifty day moving average is $18.54 and its 200 day moving average is $19.89. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a market cap of $54.92 million, a P/E ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.20 million. As a group, equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC bought a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at about $40,000. Two Sigma Investments LP purchased a new position in Tonix Pharmaceuticals during the 4th quarter valued at about $66,000. PFG Investments LLC bought a new position in Tonix Pharmaceuticals during the 4th quarter valued at approximately $72,000. Northern Trust Corp purchased a new stake in Tonix Pharmaceuticals in the 4th quarter worth approximately $162,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at approximately $526,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.